Evidence map›Paper›PMID 34166704›Full record

ArticleJournal of pharmaceutical sciences2021

Principal Component Analysis of 1D 1H Diffusion Edited NMR Spectra of Protein Therapeutics.

Korth W Elliott, Frank Delaglio, Mats Wikström, John P Marino, Luke W Arbogast

Abstract read
In one paragraph

Article in Journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Korth W ElliottInstitute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, 9600 Gudelsky Dr. Rockville, MD 20850 USA.
Frank DelaglioInstitute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, 9600 Gudelsky Dr. Rockville, MD 20850 USA.
Mats WikströmHigher Order Structure, Attribute Sciences, Amgen, Inc. One Amgen Center Dr., Thousand Oaks, CA 91320 USA.
John P MarinoInstitute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, 9600 Gudelsky Dr. Rockville, MD 20850 USA.
Luke W ArbogastInstitute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, 9600 Gudelsky Dr. Rockville, MD 20850 USA. Electronic address: luke.arbogast@nist.gov.

Funding

Intramural NIST DOC 9999-NIST
6 · The paper itself

Abstract

The one-dimensional (1D) diffusion edited proton NMR method, Protein Fingerprint by Lineshape Enhancement (PROFILE) has been demonstrated to be suitable for higher order structure (HOS) characterization of protein therapeutics including monoclonal antibodies. Recent reports in the literature have demonstrated its advantages for HOS characterization over traditional methods such as circular dichroism and Fourier-transform infrared spectroscopy. Previously, we have demonstrated that the PROFILE method is complementary with high resolution 2D methyl correlated NMR methods and how both may be deployed as a multi-modal platform to further the utility of NMR for HOS characterization. A major limitation of the PROFILE method remains its need for high signal to noise data due to its reliance on convolution difference processing and linear correlation metrics to assess spectral similarity. Here we present an alternative method for analyzing 1D diffusion edited spectra, which overcomes this limitation by using nonlinear iterative partial least squares (NIPALS) principal component analysis, and which we dub PROtein Fingerprint Observed Using NIPALS Decomposition (PROFOUND). We demonstrate that results from the PROFOUND method are robust with respect to instrument, operator and in the presence of high experimental noise and how it may be employed to provide quantitative assessment of spectral similarity.

Indexed as

Antibodies, MonoclonalCircular DichroismMagnetic Resonance SpectroscopyPrincipal Component AnalysisProton Magnetic Resonance SpectroscopyAntibodies, MonoclonalChemometricsMonoclonal antibody(s)Nuclear Magnetic Resonance (NMR) spectroscopyPrincipal component analysis (PCA)ProfoundProtein structure(s)

Identifiers

PMID34166704
PMCPMC10408412

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.